{"entity":{"id":"nct05532696","kind":"trial","name":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients","aka":[],"tldr":"A phase 1/2 trial of ABT-101 in non-small-cell lung cancer, run by Anbogen Therapeutics, Inc., now recruiting.","summary":"Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients is a phase 1/2 interventional study registered as NCT05532696 by Anbogen Therapeutics, Inc., with 61 participants planned, started 2022-09-27 and due to reach its primary completion in 2026-11. Interventions recorded: ABT-101.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05532696","url":"https://clinicaltrials.gov/study/NCT05532696"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05532696","phase":"1/2","setting":"A Phase Ib/II, Open-Label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ABT-101 in Patients With Advanced Solid Tumors and HER2 Exon 20 Insertions Mutated Non- Small Cell Lung Cancer","sponsor":"Anbogen Therapeutics, Inc.","enrolled":61,"outcomes":[]},"route":"/trials/nct05532696/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}